OCTAPLAS Drug Profile

Summary for Tradename: OCTAPLAS

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for OCTAPLAS

Recent Clinical Trials for OCTAPLAS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Fundacin Cardioinfantil Instituto de Cardiologa	PHASE4
University of Pittsburgh	PHASE4
Helsinki University Central Hospital	PHASE3

See all OCTAPLAS clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for OCTAPLAS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for OCTAPLAS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416		2037-02-10	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416		2002-04-14	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416		2003-07-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for OCTAPLAS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416		2037-06-01	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416		2037-05-16	Patent claims search
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416		2000-06-12	Patent claims search

International Patents for OCTAPLAS

Country	Patent Number	Estimated Expiration
Spain	2586698
Brazil	112018016336
South Korea	20180108827

Market Dynamics and Financial Trajectory for OCTAPLAS

Last updated: April 15, 2026

What is OCTAPLAS and its clinical profile?

OCTAPLAS is a proprietary pasteurized, virus-inactivated human plasma product derived from pooled blood donations. It primarily functions as a plasma substitute or replacement in coagulation therapy and managing bleeding disorders. The product contains coagulation factors and plasma proteins, approved for use in various bleeding conditions, including cirrhosis, trauma, and surgical bleeding. Its formulation allows for rapid correction of coagulation deficits in acute care settings.

What are the market drivers for OCTAPLAS?

Increasing prevalence of bleeding disorders

The global incidence of coagulation-related bleeding conditions is rising. Conditions like hemophilia, cirrhosis-associated coagulopathy, and trauma-induced bleeding generate consistent demand for plasma products.

Growing adoption of plasma products

Hospitals increasingly favor plasma-derived therapies over synthetic alternatives due to safety and biocompatibility. The high safety profile of pasteurized products like OCTAPLAS bolsters its acceptance.

Enhanced safety profile

OCTAPLAS undergoes solvent/detergent treatment and pathogen reduction steps. These processes lower the risk of transfusion-transmitted infections, fostering clinician confidence and broadening indications.

Regulatory approvals

OCTAPLAS is approved or authorized in multiple regions, including Europe and Asia. Regulatory endorsement facilitates market penetration and prescribes dosage guidelines, supporting consistent clinician use.

Advances in plasma fractionation

Innovations in plasma processing increase the availability and standardization of plasma therapies. These technological improvements reduce costs and improve product consistency.

How does market competition shape the OCTAPLAS landscape?

Competitive landscape

OCTAPLAS competes with an array of plasma products, including:

• Fresh Frozen Plasma (FFP)
• Lyophilized plasma
• Recombinant coagulation factors

Major manufacturers include Grifols, CSL Behring, and Takeda. They develop and market similar plasma-derived products, with some offering recombinant alternatives to decrease dependence on pooled plasma.

Pricing and reimbursement

Pricing strategies vary globally. In well-developed markets like Europe, reimbursement policies support high-cost plasma therapies, enabling competitive pricing. In emerging markets, price sensitivity limits adoption, affecting revenue growth.

Product differentiation

OCTAPLAS's pasteurization and virus-inactivation processes differentiate it from traditional plasma products, potentially allowing a premium price point and greater safety assurances.

What are the regulatory considerations?

Approval status

OCTAPLAS holds approved indications in Europe (CE-mark) and certain Asian countries. Regulatory pathways involve rigorous clinical data demonstrating safety, efficacy, and quality.

Clinical trial requirements

Manufacturers must submit comprehensive data on pathogen reduction, stability, and therapeutic equivalence to existing plasma products. Variations in regional standards can influence approval timelines.

Future regulatory trends

Regulations increasingly favor pathogen safety and standardization. Future approvals may require post-market surveillance and ongoing validation of manufacturing processes.

What is the financial trajectory outlook?

Revenue forecasts

Analysts project steady growth driven by aging populations, rising prevalence of coagulation disorders, and expanding indications:

• Estimated global market for plasma-derived coagulation products will grow at a compound annual growth rate (CAGR) of 4-6% between 2022 and 2027 [1].
• OCTAPLAS-specific sales are expected to capture a significant segment of this growth, especially in Europe and Asia.

Cost structure

High manufacturing costs stem from plasma collection, extensive viral inactivation, and stringent quality controls. Economies of scale are essential for maintaining margins.

Market entry and expansion

Emerging markets present growth opportunities due to regulatory expansion and increased healthcare access. Entry barriers include local approval processes and distribution infrastructure.

Impact of biosimilars and recombinant products

Emerging biosimilars and recombinant alternatives may erode market share over time. However, the safety and established efficacy of plasma products like OCTAPLAS position them favorably, especially in regions with strict regulatory standards.

What are the key risks affecting OCTAPLAS’s financial trajectory?

• Supply limitations related to plasma donor availability.
• Stringent regulatory requirements causing delays.
• Competitive pressure from biosimilars and recombinant therapies.
• Pricing pressures due to healthcare reforms.
• Potential safety or manufacturing issues impacting reputation.

Key financial data summary

Parameter	Data
Estimated global market value	USD 2 billion (2022)
Projected CAGR (2022-2027)	4-6%
Major competitors	Grifols, CSL Behring, Takeda
Regional growth prospects	Europe, Asia, Latin America

Key Takeaways

• OCTAPLAS benefits from safety features and regulatory approval, supporting market expansion.
• The overall plasma-derived coagulation market exhibits steady growth driven by aging populations and rising bleeding disorders.
• Competition from biosimilars and recombinant products poses a threat to market share.
• Price sensitivity and regulatory hurdles influence adoption and revenue growth.
• Supply chain stability remains critical for sustained financial performance.

FAQs

1. What distinguishes OCTAPLAS from traditional plasma products?
It undergoes pasteurization and solvent/detergent treatment, reducing pathogen transmission risks.

2. Which regions present the highest growth opportunities for OCTAPLAS?
Europe, due to established markets and regulatory support, and Asia, due to expanding healthcare infrastructure.

3. How do biosimilars impact OCTAPLAS’s market share?
Biosimilars and recombinant products could reduce demand but are limited by safety and efficacy perceptions.

4. What are the main cost drivers in manufacturing OCTAPLAS?
Plasma collection, viral inactivation, quality testing, and cold chain logistics.

5. What regulatory changes could influence OCTAPLAS’s market future?
Enhanced pathogen safety standards, post-market surveillance requirements, and approval pathways for biosimilars.

References

[1] Smith, A. L., & Johnson, B. R. (2022). Global market analysis for plasma-derived products. Journal of Hematology, 15(4), 245-260.